• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·France·Healthcare·EMEIS.PA
Share

emeis Societe anonyme Stocks

€ 9.99Last Updated 20.10.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

€ 1.88B

€ 9.99
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Emeis Société anonyme operates as a prominent provider of diverse healthcare services, encompassing the management of nursing homes, assisted-living facilities, specialized post-acute and rehabilitation hospitals, and psychiatric treatment centers. Within its elderly care residences, the company delivers tailored support alongside comprehensive logistical and residential amenities, including comfortable accommodation, meal services, laundry, and room maintenance. These facilities also enrich residents' lives with a variety of daily events, recreational activities, and therapeutic workshops. Emeis's post-acute and rehabilitation hospitals are equipped to treat a wide array of medical conditions, such as geriatric issues, musculoskeletal and neurological disorders, cardiovascular and hematological ailments, oncology recovery, and care for individuals in persistent vegetative or minimally conscious states. The psychiatric hospitals address an extensive spectrum of mental health concerns, ranging from mood, anxiety, and obsessive-compulsive disorders to addictions, eating disorders, sleep disturbances, personality disorders, age-related psychiatric conditions, psychosis, and stress-induced conditions like burnout, chronic fatigue syndrome, fibromyalgia, psychosomatic issues, and post-traumatic stress disorder. Furthermore, they offer specialized psychiatric care for geriatrics, children, young adults, and parent-child dynamics, serving both public and private patients. Complementing its institutional offerings, Emeis also provides comprehensive home care solutions. These include practical domestic assistance such as cleaning, meal preparation, ironing, gardening, and running errands; daily living support encompassing day or night supervision and aid with hygiene and meals; and mobility assistance. Founded in 1989 and headquartered in Puteaux, France, the company maintains an expansive international presence, with operations spanning numerous countries across Europe, Latin America, and Asia, including France, Belgium, Spain, Italy, Ireland, Switzerland, Austria, Germany, the Czech Republic, Poland, the Netherlands, Luxembourg, Portugal, Brazil, Russia, Slovenia, Uruguay, Colombia, Mexico, Chile, Latvia, Croatia, and China.

Company Valuation

Undervalued
6/7

Considering past and projected metrics, the stock is 'cheaper' than its peers. Specifically, the stock is neutral on EV/EBITDA, underpriced on P/FC.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Very favourable
7/7

The average target price of EMEIS.PA is 16.1 and suggests 61.1% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

21.10.2026 16:10

Shares of software developer Braze soared 50%. Salesforce is set to acquire it for the "wow factor."

21.10.2026 15:51

It's Not Just the War: Morgan Stanley Doesn't Expect the Fuel Market to Ease Until Mid-2027

21.10.2026 15:46

Morning in New York: Stress Tests for the Tech Sector Continue

21.10.2026 15:46

Losses Exceeding $80 Billion and Rapidly Rising Costs: What the WSJ Learned from Anthropic's Prospectus

21.10.2026 14:58

Where Can You Drive the Tesla Roadster? This and Other Questions About Musk's "Rocket on Wheels"

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026